Cancer immunotherapy faces challenges in side effects and cost

Recent developments in cancer immunotherapy highlight both significant medical breakthroughs and substantial challenges regarding side effects and economic accessibility.

Researchers at the University of Texas MD Anderson Cancer Center have discovered that inflammatory arthritis triggered by immune checkpoint inhibitors may be driven by immune memory. The study, published in Cancer Immunology Research, suggests that immune cells can reactivate long after treatment, potentially causing arthritis flares that are more severe than the initial episode. This finding may allow doctors to better identify at-risk patients and target specific cells without compromising the cancer-fighting response.

Simultaneously, the high cost of these biologics remains a major barrier to equitable care. In the United States, per-patient costs for therapies such as pembrolizumab can exceed $160,000. These costs are driven by complex factors including patent exclusivity, which may extend market dominance into the 2030s, and variations in billing structures between hospitals and outpatient clinics. In emerging economies, the financial burden of these treatments often exceeds the median annual household income, widening the gap between scientific innovation and patient access.